Allergan, Inc. Receives FDA Approval for LUMIGAN(R) 0.01% as First-Line Therapy Indicated for the Reduction of Elevated Intraocular Pressure in Glaucoma Patients
In order to access this content you must be logged in and have a subscription to Pharmalicensing Intelligence.
Pharmalicensing Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.
Subscribe now for instant access to the benefits Pharmalicensing Intelligence has to offer. Find out more
If you want to find out more about the company visit Allergan profile.
Nov 2010 - 128 pages - $500
Dec 2010 - 29 pages - $500
Mar 2009 - 86 pages - $5,700
Feb 2011 - 75 pages - $500
Apr 2011 - 5 pages - $500
Dec 2010 - 5 pages - $500
Dec 2006 - 131 pages - $5,700
May 2011 - 5 pages - $500
Jan 2011 - 4 pages - $500
Nov 2010 - 384 pages - $1,495